Business Wire

Forrester Announces Full Conference Agenda For Technology & Innovation Summit EMEA 2025

24.7.2025 11:00:00 CEST | Business Wire | Press Release

Share

Forrester (Nasdaq: FORR) today announced the agenda for its Technology & Innovation Summit EMEA 2025, taking place in London and digitally on 8–10 October. As tech leaders confront relentless disruption — from AI breakthroughs and cost pressures to geopolitical instability — the ability to adapt quickly is becoming a competitive advantage. This year’s event is designed to empower leaders to master tech mayhem by harnessing AI, computing, and agentic systems for smarter automation and faster decision-making while refining cloud strategies for composability, sovereignty, and security.

At the event, tech, data, analytics, and cybersecurity leaders will immerse themselves in engaging, hands-on experiences, featuring keynotes, breakouts, roundtables, case studies, workshops, and one-on-one analyst sessions, to tackle AI-driven disruption, rising costs, and geopolitical turbulence.

Noteworthy keynote sessions include:

  • Agentic To AGI: It’s The Journey, Not The Destination. In this keynote, leaders will learn to cut through the AI hype by seeing agentic AI and artificial general intelligence (AGI) as a continuum and anticipating key milestones for the evolving AI journey.
  • Use The AI Moment To Achieve Your High-Performance Ambitions. This keynote session will reveal how leaders can overcome AI challenges through business alignment, streamlined governance, and strong data foundations.
  • AI Inside: The Rise Of The Intelligent IT Operating Model. In this keynote, leaders will discover how AI transforms IT into an adaptive, intelligent system that can reshape governance, strategy, and operations.
  • FinOps And Beyond: Scaling Tech For The Future Without Breaking The Bank. This keynote will outline how integrating FinOps with IT financial management drives strategic budgeting and better financial outcomes.
  • Data Readiness Is The Number One Factor For AI Results. During this keynote, leaders will understand the critical role of data strategy and governance in improving AI outcomes, reducing costs, and ensuring responsibility.
  • In Trust We Build: Balancing Risk And Realising AI’s Potential. In this keynote, leaders will learn to balance AI risk mitigation with innovation by operationalising trustworthy AI for sustainable growth.

“Technology leaders are facing unprecedented challenges from AI, automation, and evolving digital demands while simultaneously managing legacy systems and rising cybersecurity threats,” said Pascal Matzke, Forrester VP and research director and T&I Summit EMEA event host. “They must prove the ROI of tech investments, navigate cost pressures, and align closely with business goals. Technology & Innovation Summit EMEA 2025 will equip leaders with actionable insights and innovative strategies to chart a course for sustainable growth.”

At the event, Forrester will also celebrate its Technology Awards winners to recognise organisations that have enhanced business outcomes with their IT capabilities. Additionally, T&I Summit EMEA 2025 will feature specialised programmes, including the invitation-only Executive Leadership Exchange (ELE) for C-suite technology and data executives and the Forrester Women’s Leadership Programme, which fosters community and advancement for women in tech. The Summit also offers certification courses on high-performance IT strategy and AI and data readiness, equipping leaders with actionable strategies and tools to evaluate and enhance their organisations’ capabilities.

Resources:

About Forrester

Forrester (Nasdaq: FORR) is one of the world’s most influential research and advisory firms. We empower leaders in technology, customer experience, digital, marketing, sales, and product functions to be bold at work and accelerate growth through customer obsession. Our unique research and continuous guidance model helps executives and their teams achieve their initiatives and outcomes faster and with confidence. To learn more, visit Forrester.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250724777475/en/

Contacts

Press contacts:
Hannah Segvich
hsegvoch@forrester.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye